While gains of 1–2% were evident for Alzheimer’s disease and Alzheimer’s pathologic change, we found that the improvement in performance was most pronounced for isolated non-Alzheimer’s disease pathologic change (i.e. tau and/or neurodegeneration change in the context of normal amyloid) or concomitant Alzheimer’s and non-Alzheimer’s pathology states (defined as abnormal amyloid and neurodegeneration biomarkers in the absence of tau change). This evidence concerns the gene MAPT and Alzheimer disease.